Skip to Content

Asparaginase escherichia coli Disease Interactions

There are 6 disease interactions with asparaginase escherichia coli:

Major

Asparaginase (applies to asparaginase escherichia coli) coagulation abnormalities/bleeding

Major Potential Hazard, Moderate plausibility. Applicable conditions: Coagulation Defect

Impaired synthesis of fibrinogen and decreased serum levels of clotting factors have been reported in patients in asparaginase therapy. Bleeding has been observed in patients with coagulation disorders. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Therapy with asparaginase should be administered cautiously to patients with coagulation disorders. The use of asparaginase is contraindicated in patients with serious bleeding or history of serious hemorrhagic events with prior to asparaginase therapy.

References

  1. "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.
Major

Asparaginase (applies to asparaginase escherichia coli) pancreatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Pancreatitis

The use of asparaginase is contraindicated in patients with pancreatitis or a history of pancreatitis. Pegaspargase can cause decreased insulin synthesis or may cause inflammation and/or necrosis of cells of the pancreas. Fulminant and fatal pancreatitis has occurred. Clinical monitoring of pancreatic function, including serum amylase levels, is recommended.

References

  1. "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.
Moderate

Asparaginase (applies to asparaginase escherichia coli) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Reversible liver abnormalities such as elevated liver transaminase and bilirubin levels and decreased albumin synthesis have been reported during asparaginase therapy. Fatty changes in the liver have been noted. Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Therapy with asparaginase should be administered cautiously to patients with or predisposed to compromised hepatic function. Clinical monitoring of hepatic function is recommended.

References

  1. "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.
Moderate

Asparaginase (applies to asparaginase escherichia coli) hyperglycemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Glucose intolerance has been reported in patients receiving asparaginase. In some cases glucose intolerance may be irreversible. Monitor glucose levels in patients at baseline and periodically during treatment. Administer insulin therapy as necessary in patients with hyperglycemia. Therapy with asparaginase should be administered cautiously in patients with diabetes mellitus.

References

  1. "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.
Moderate

Asparaginase (applies to asparaginase escherichia coli) myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Transient myelosuppression has been observed during asparaginase therapy, however its myelosuppressive effect has not been well characterized. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Therapy with asparaginase should be administered cautiously in patients with severe bone marrow suppression.

References

  1. "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.
Minor

Asparaginase (applies to asparaginase escherichia coli) mental status changes

Minor Potential Hazard, Low plausibility. Applicable conditions: Psychosis

Reversible CNS symptoms, varying from mild to severe, such as depression, confusion, agitation, or hallucinations have been reported. Patients with existing or predisposition to psychoses or emotional disorders may be at increase risk for CNS symptoms associated with asparaginase therapy. Clinical monitoring of mental status is recommended.

References

  1. "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.

Asparaginase escherichia coli drug interactions

There are 449 drug interactions with asparaginase escherichia coli

Asparaginase escherichia coli alcohol/food interactions

There is 1 alcohol/food interaction with asparaginase escherichia coli

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.